Serum microRNAs – potent biomarkers for radiation biodosimetry by Tomasik, Bartłomiej et al.
Serum microRNAs – potent
biomarkers for radiation biodosimetry
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Tomasik, Bartłomiej, Wojciech Fendler, and Dipanjan Chowdhury.
2018. “Serum microRNAs – potent biomarkers for radiation
biodosimetry.” Oncotarget 9 (18): 14038-14039. doi:10.18632/
oncotarget.24381. http://dx.doi.org/10.18632/oncotarget.24381.
Published Version doi:10.18632/oncotarget.24381
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:35981910
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Oncotarget14038www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/              Oncotarget, 2018, Vol. 9, (No. 18), pp: 14038-14039
Serum microRNAs – potent biomarkers for radiation 
biodosimetry
Bartłomiej Tomasik, Wojciech Fendler and Dipanjan Chowdhury
Exposure to high doses of radiation poses a 
significant threat to human life. The current methods of 
accurately predicting the biological effect of radiation are 
still dependent on the manifestation of symptoms or rely 
on technically complex and time-consuming tests such as 
the dicentric chromosome assay [1]. One of the primary 
limitations of this approach is that it cannot be easily 
implemented at the point of care, making efficient triage 
impossible. Using a commercial dosimeter, which needs 
to be worn at the time of the event, is similarly unfeasible 
in a population facing accidental radiation exposure. 
Therefore, there is an acute need for the identification of 
radiation-specific biomarkers that are capable of rapid 
predicting latent damage to various organs and systems 
immediately after radiation exposure. 
MicroRNAs (miRNAs) are non-coding RNAs of 
19-22 nucleotides that regulate diverse cellular processes, 
and serum circulating miRNAs have recently emerged as 
promising biomarkers for diagnosing various malignancies 
and predicting treatment responses [2]. Attempts have 
been made to use serum miRNAs as biodosimeters, 
however, the overlap and replicability of the published 
results were disappointingly low [3, 4]. The possible 
explanation for those discrepancies could be caused by 
differences between experimental models and applied 
methodologies of quantifying circulating miRNAs. 
In 2015 our team identified a panel of serum 
miRNAs that were differentially expressed in response to 
total body irradiation (TBI) in C57BL/6J mice 24 hours 
after exposure [5]. The results indicate that the miRNA-
based assay provided robust and repeatable results 
diagnostic of different doses of radiation, including 
a clinically-efficient separation of sublethal (6.5 Gy) 
and lethal doses (8 Gy) lethal doses. Additionally, 
they demonstrated that the serum profile of miRNAs 
associated with lethal irradiation reverted to normal 
range if amifostine - a radioprotective agent - was given 
before irradiation with the 8Gy dose. This suggested 
that the serum miRNA signature may serve not only as a 
biodosimeter but is indicative of the biological impact of 
irradiation linked to the irreversible destruction of bone 
marrow. 
The results obtained in a mouse model are not 
however easy to translate into clinical practice. Given 
the impossibility to test the efficacy of our biomarkers in 
humans directly, we sought to develop an experimental 
model mimicking the high-dose irradiation scenario 
as accurately as possible. Thus, we decided to test our 
miRNA-based diagnostic tool for lethal irradiation in 
nonhuman primates (NHPs) [6]. We studied two large 
cohorts (a primary group of 48 and a validation group of 
54 animals) of healthy NHPs (Macaca mulatta, Chinese 
substrain) subjected to total doses of radiation ranging 
from 5.8Gy (LD30/60) to 7.2Gy (LD70/60) during a drug 
trial on radiation mitigating agents. We identified seven 
miRNAs (miR-30a, miR-126, miR-133a, miR-133b, 
miR-150, miR-215 and miR-375) that were altered by 
irradiation in both mice and NHPs, proving that this pattern 
is evolutionarily conserved, most likely due to conserved 
transcription factor binding sites within promoter regions 
of genomic miRNA-coding sequences. Interestingly, 
bioinformatic analyses revealed seven transcription factors 
that are predicted to bind to the promoter sequences of all 
seven conserved radiation-responsive miRNAs in mice, 
macaques and humans. It was demonstrated that serum 
concentrations of the evolutionarily-conserved miRNAs 
miR-30a, miR-126, and miR-375 correlated with the 
efficacy of a radioprotective agent, γ-tocotrienol (GT3). 
However, the concentrations of remaining four conserved 
miRNAs showed a greater changed in expression change 
to radiation than that observed in controls. This suggests 
that the processes regulated by GT3 differ from those 
modulated by amifostine, however, this issue requires 
in-depth mechanistic studies. In addition, we developed 
a classification tool trimmed down to only three miRNAs 
(miR-133b, miR-215, and miR-375) which accurately 
distinguished NHPs exposed to radiation from those who 
were not. We also found striking evidence of miRNAs 
sex-dependent changes in response to radiation: miR-
16-2 was associated with survival and its decreased 
expression was predictive of death both in males and 
females, however, the males showed half the pre- and 
post-exposure expression than females. Therefore, the 
design of an effective prognostic model required us to 
account for the sex of the animals, and by doing so we 
showed that we can reproducibly predict radiation-induced 
mortality in NHPs using a model consisting of miR-30a 
and miR-126. Further studies are required to determine 
whether radiation-induced serum miRNA signatures are 
tissue-specific or related predominantly to damage of the 
hematopoietic system. 
Unresolved before miRNA-based tests or drugs may 
be put into clinical practice. The biological mechanism of 
secreting the miRNAs into the serum remains unknown, 
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as are the regulatory mechanisms leading to differential 
expression of radiation-inducible miRNAs depending 
on sex and their complex interactions with radiation 
mitigating or radioprotective agents. Moreover, if the 
observed miRNAs are exosome-bound, they could actively 
participate in cell-to-cell transfer and play an active role 
in mitigating radiation-induced damage, rather than acting 
only as biomarkers. However, studies suggest that novel 
biodosimetric miRNA-based tools and even RNA-based 
drugs will be within our reach in the near future.
Furthermore, the utility of miRNAs in detecting 
and quantifying radiation exposure may be potentially 
translated to the field of radiotherapy. Our clinical paper 
showed that circulating serum miRNA profile changes in 
response to the delivered dose of radiation of radiation in 
patients treated for lung cancer [7], while another report 
confirmed that miRNAs could be used in personalized 
radiotherapy to achieve the best tumor control with 
minimal healthy tissue toxicity [8]. Such studies are of 
utmost importance because normal tissue toxicity prevents 
dose escalation in patients undergoing radiotherapy.
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